SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around positive sentiment and long-term holding, emphasizing the "WAGMITHON" and strong community support. The community is speculating about a potential CMC listing while highlighting the token's solid liquidity and cultural appeal within the $SOL ecosystem. Discussions also focus on the project's doxxed team and consistent growth.

CATULU | THE THREADED FAMILIAR  Catulu is like Tamagotchi for the Twitter age — except your pet lives on the timeline, and the more you play, the more everyone sees it.  Platform & Core Mechanics Platform: Twitter + Web3 (Solana) Core Loop: Tweeting = Feeding, Cleansing, Training Tokens: $CATULU (native currency of the ecosystem)   Level up your characters to unlock more avatar images , get into top ranks on leaderboard and earn LP rewards.

CATULU

CATULU is trending as community members highlight its availability on Phantom Wallet and anticipate potential listings. The conversation is fueled by bullish sentiment, with many users expressing excitement and urging others to buy. Discussions also include comparisons to other meme coins like UPDOG and PEPE.

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is trending as community members highlight its potential within the Avalanche network, noting its fully diluted supply and predictions of significant influx of RWAs; the overall sentiment suggests a possible run. Some users point to Forbes coverage and increasing TVL as reasons for optimism, while others focus on tokenomics and compare it to other DeFi projects.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE is trending as its community rallies around ongoing development and upcoming utilities, emphasizing their daily 'grind' and active engagement. Community members are excited about opportunities to earn more $BROKE through Telegram games and anticipate a token burn event. Despite some skepticism, the community remains focused on building value and reversing recent price action, highlighting its resilience within the Solana ecosystem.

GME Ethereum

GME Ethereum is trending as the community anticipates a "God Candle" and a tweet from Roaring Kitty, potentially signaling a major surge. Discussions also revolve around JTR Crypto (JTRAMBO) and its recent market cap milestones, with community members emphasizing a "buy and hold" strategy. However, some users are raising concerns about the legitimacy of the project and its affiliation with GameStop.

Green Satoshi Token

GSTSOL is gaining attention as traders discuss its potential for a significant breakout, with some pointing to technical indicators and increasing volume as bullish signals. The community is closely watching for a catalyst that could trigger a rally, while also considering factors like its low market cap and past performance. Sentiment is mixed, with some expressing frustration over previous price action and others remaining optimistic about future gains.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions about stablecoin regulation and increasing adoption across various blockchains like Solana. Community members are actively discussing USDC's role in DeFi, cross-chain transfers, and partnerships with major players such as Visa. There's also conversation around potential competition from other stablecoins and real-world asset tokenization initiatives.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around the joke-based Solana token and its 19-month anniversary. The community is actively asking "What's UpDog?" and highlighting its listing on the Jupiter Strict List while encouraging others to load up on $SOL clips.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the token was recently listed on Robinhood, though some traders are noting a lack of immediate price surge following the news. Community members are discussing potential catalysts, including the Valhalla game tournament and burn mechanisms, while also comparing Floki's potential to other meme coins like Dogecoin and Shiba Inu during the anticipated altcoin season.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Cel-Sci is trending as community members anticipate news regarding a potential partnership with Dallah Pharma and the related SFDA application for Multikine, an immunotherapy treatment. The community expresses optimism about Multikine's potential in the Saudi Arabian market, aligning with Saudi Vision 2030, but also discusses the company's history and possible future dilution. Chatter revolves around potential catalysts and speculation about a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts

Latest Ratings for LYEL
 DateFirmActionFromTo Jan 2022Morgan StanleyMaintainsOverweight Jul 2021Morgan StanleyInitiates Coverage OnOverweight Jul 2021B of A SecuritiesInitiates Coverage OnBuy...

WisdomTree, Inc. ($WT)Shares of WisdomTree, which offers a suite of exchange-traded and blockchain technology products, reported third-quarter earnings per share (EPS) of $0.18 compared to $0.10 per share a year-ago. This beat the consensus estimate of $0.18, according to Yahoo Finance.The shares climbed 4.50% to $10.85 as of 9:00 am ET, in premarket trading.WisdomTree’s assets under management at the end of the third quarter was $112.6 million, up from $109.7 million at the end of the second quarter. Operating revenue came in at $109.5 million compared to the $90.4 million reported for a year earlier. This was slightly shy of the consensus estimate of $110.07 million.<figure class="image"><a href="https://stocktwits.com/symbol/WT"><img style="aspect-ratio:637/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/wt_sentiment_34b5aa54e0.png" alt="wt-sentiment.png" width="637" height="135"></a><figcaption>WT sentiment and message volume October 25, 2024 premarket as of 9:00 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Retail sentiment was ‘extremely bullish’ (95/100) with message volume reducing from a day ago, yet at ‘high.’Lyell Immunopharma, Inc. ($LYEL)Small-cap Lyell Immunopharma, a clinical-stage CART T-cell therapy biotech, said late Thursday that it has entered into a definitive agreement to acquire privately-held&nbsp; ImmPACT Bio USA Inc for $30 million in cash and 37.5 million in stock.Through the acquisition, Lyell Immunopharma will acquire worldwide rights to ImmPACT’s pipeline. The company will prioritize the development of IMPT-314 for treating B-cell lymphoma, a type of blood cancer.ImmPACT shareholders are also eligible to receive contingent consideration of 12.5 million of Lyell Immunopharma stock as milestone-based payment as well as royalties on net sales.The deal has been vetted by the board of both companies and is expected to close in the fourth quarter.The stock gained 0.94% to $1.10 in premarket trading.DexCom, Inc. ($DXCM)Glucose monitoring device manufacturer Dexcom’s shares fell in premarket trading but retail sentiment remains ‘extremely bullish.'<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:632/145;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/dxcm_sentiment_f6ce5575e8.png" alt="dxcm-sentiment.png" width="632" height="145"></a><figcaption>&nbsp;DXCM sentiment and message volume October 25, 2024 premarket as of 9:00 am ET | Source:&nbsp;Stocktwits</figcaption></figure>DexCom’s third-quarter non-GAAP EPS came in at $0.45 compared to the consensus estimate of $0.43. Revenue rose 2% year-over-year from $975 million to $994.2 million. Analysts, on average, estimated a modest $990.44 million for the quarter.&nbsp;The double beat is a welcome relief after the company missed top-line expectations in the second quarter.Dexcom announced a management transition as Teri Lawver, who serves as chief commercial officer, is set to retire by the year-end. Sayer will assume her responsibilities as the company begins a search for a replacement.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dexcom-stock-plunges-despite-q3-beat-but-retail-sentiment-improves/cJ2lHI0R7u">Dexcom Stock Plunges Despite Q3 Beat But Retail Sentiment Improves</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Dexcom and WisdomTree has cheered retailers with their earnings reports, and Lyell with an M&A transaction.

WisdomTree, Lyell Immunobiopharma, DexCom Among Stocks Retailers Are Most Bullish In Friday's Premarket

Earnings news and an M&A deal have improved retail sentiment toward these 3 stocks in Friday's premarket.

Equity

Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial

Lyell Immunopharma shares fell following the release of initial clinical data from its Phase 1 trial of LYL797, a reprogrammed CAR T-cell product. The company reported some severe cases reported in...

Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 4.9%

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) rose 4.9% during mid-day trading on Thursday . The company traded as high as $2.17 and last traded at $2.16. Approximately 21,770...

Lyell Immunopharma (NASDAQ:LYEL) Trading 5.9% Higher

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s stock price traded up 5.9% during mid-day trading on Thursday . The stock traded as high as $2.17 and last traded at $2.16. 158,847 shares...

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON 19 March 2024 -- CHARM Therapeutics ( CHARM , The Company ), a 3D deep-learning research company...

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for LYL845 for the treatment of melanomaExpect to...

Commit To Buy Lyell Immunopharma At $2.50, Earn 57.3% Annualized Using Options

Investors eyeing a purchase of Lyell Immunopharma Inc (LYEL) shares, but tentative about paying the going market price of 2.84/share, might benefit from considering selling puts among the...

Lyell Immunopharma Announces Participation in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Lyell Immunopharma Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$17.75
Prev Close	$15.81
Open	$15.85
Dividend Yield	0.00%
50-Day Moving Average	$12.18
Beta	1.67
Avg. Volume	60,974.95
PE Ratio	-0.65

52-Week High	$30.00
52-Week Low	$7.65
Market Capitalization	$303.73M
EPS (Annual)	-$26.23
Price to Book	0.78
Revenue Per Employee	$203.33
Enterprise Value/EBITDA	N/A

LYEL
Lyell Immunopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LYEL News

LYEL Lyell Immunopharma Inc